CKD and obesity
How big a problem is the coexistence of chronic kidney disease (CKD) and obesity? In a person starting renal replacement therapy, is obesity or malnutrition a greater risk?
How big a problem is the coexistence of chronic kidney disease (CKD) and obesity? In a person starting renal replacement therapy, is obesity or malnutrition a greater risk?
What new problems have arisen in relation to novel oncology therapies in patients with coexisting kidney disease?
What is the risk of urinary stone formation (uric acid, calcium oxalate) in patients with CKD of variable severity?
What is the importance of animal models in kidney disease research in humans? What have been the directions and results of studies so far?
Which imaging method, ultrasonography or CT, if both are available, should be performed first in a person with renal colic?
What is the most relevant evidence from studies examining the relationship between the gut microbiota and common kidney or kidney-related diseases?
Is diet or, more broadly, nutritional treatment important in the course of chronic disease at its various stages?
Have there been significant advances in the treatment of IgA nephropathy in recent years?
As of today, can we consider any of the available methods of nonspecific nephroprotection—that is, ACE inhibitors, ARBs, SGLT-2 inhibitors, or aldosterone receptor inhibitors—superior to others?
Is any of the SGLT-2 inhibitors more “kidney friendly” and should therefore be preferred by nephrologists?